• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 3. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 4. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acid esters
• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of 3-(2-Ethoxycarbonylethyl)phenylboronic acid (CAS: 913835-82-2) in Chemical Biology and Pharmaceutical Research

3-(2-Ethoxycarbonylethyl)phenylboronic acid (CAS: 913835-82-2) has emerged as a versatile compound in chemical biology and pharmaceutical research due to its unique structural properties and reactivity. This boronic acid derivative is increasingly recognized for its role in Suzuki-Miyaura cross-coupling reactions, a cornerstone in the synthesis of complex organic molecules, including pharmaceuticals. Recent studies have highlighted its potential in drug discovery, particularly in the development of proteolysis-targeting chimeras (PROTACs) and boron-containing therapeutics. This research brief synthesizes the latest findings on this compound, focusing on its applications, mechanisms, and future directions.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 3-(2-Ethoxycarbonylethyl)phenylboronic acid as a key intermediate in the synthesis of novel kinase inhibitors. The study demonstrated that the boronic acid moiety facilitates efficient cross-coupling with halogenated heterocycles, yielding compounds with enhanced selectivity for tyrosine kinases. This approach has significant implications for targeted cancer therapies, where kinase inhibition is a critical strategy. The researchers also noted the compound's stability under physiological conditions, making it a promising candidate for further preclinical evaluation.

In the realm of chemical biology, 3-(2-Ethoxycarbonylethyl)phenylboronic acid has been employed as a molecular probe to study protein-ligand interactions. A recent Nature Chemical Biology article detailed its use in dynamic combinatorial chemistry (DCC) to identify high-affinity binders for carbohydrate-recognizing proteins. The boronic acid group's ability to form reversible covalent bonds with diols was leveraged to screen libraries of potential inhibitors for lectins involved in immune regulation. This innovative methodology opens new avenues for discovering allosteric modulators of protein function.

Another groundbreaking application was reported in a 2024 ACS Central Science paper, where the compound served as a building block for boron neutron capture therapy (BNCT) agents. The researchers designed a series of tumor-targeting molecules incorporating 3-(2-Ethoxycarbonylethyl)phenylboronic acid, which exhibited preferential accumulation in cancer cells. Upon neutron irradiation, the boron-10 nuclei released high-energy particles, leading to localized tumor cell destruction. This study represents a significant step forward in the development of precision radiotherapy.

Despite these advances, challenges remain in optimizing the pharmacokinetic properties of boronic acid-containing compounds. A 2023 review in Chemical Reviews highlighted the need for improved strategies to address the rapid metabolism and potential off-target effects associated with this class of molecules. However, the unique reactivity of 3-(2-Ethoxycarbonylethyl)phenylboronic acid continues to inspire innovative solutions, such as prodrug approaches and nanoparticle-based delivery systems.

Looking ahead, the integration of computational chemistry and machine learning is expected to accelerate the discovery of new applications for 3-(2-Ethoxycarbonylethyl)phenylboronic acid. Recent work published in Science Advances demonstrated the successful prediction of boronic acid reactivity patterns using quantum mechanical calculations, paving the way for rational design of next-generation therapeutics. As research in this area progresses, this compound is poised to play an increasingly important role in bridging chemical synthesis with biological applications.

• 92243-74-8(4-Ethoxycarbonylmethylphenylboronic acid)
• 1072946-56-5(5-(3-Boronophenyl)pentanoic acid)
• 166316-48-9(4-(2-carboxyethyl)phenylboronic acid)
• 660440-57-3(4-(2-Ethoxycarbonylethyl)phenylboronic acid)
• 643094-11-5([3-(2-methoxy-2-oxoethyl)phenyl]boronic acid)
• 850568-44-4([4-(3-methoxy-3-oxopropyl)phenyl]boronic acid)
• 833472-82-5(3-(2-Methoxycarbonylethyl)phenylboronic acid)
• 693803-17-7(3-(2-Carboxyethyl)phenylboronic acid)
• 1072946-57-6(3-(4-Carboethoxybutyl)phenylboronic Acid)
• 1256345-69-3((3-(2-Ethoxy-2-oxoethyl)phenyl)boronic acid)